Shots:
- FDA has approved Foundayo along with lifestyle intervention for obese/overweight adults with weight-related medical problems; Foundayo will be available via LillyDirect beginning Apr 6, 2026
- Approval was backed by the ATTAIN program, incl. ATTAIN-1, where Foundayo showed weight loss of 27.3 lbs (12.4%) vs 2.2 lbs (0.9%) with PBO at the highest dose, with overall loss of 25 lbs (11.1%) vs 5.3 lbs (2.1%), alongside reductions in CV risk markers across all doses
- Eli Lilly aims to improve access to Foundayo with pricing from $25/month (insured), $149/month (self-pay), & ~$50/month for eligible Medicare Part D pts (from Jul 2026), while advancing filings in 40+ countries for weight management & T2D, with launch shortly after approval
Ref: Eli Lilly| Image: Eli Lilly | Press Release
Related News: Eli Lilly Reports Topline P-III (ATTAIN-MAINTAIN) Trial Results of Orforglipron for Weight Loss Maintenance
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
